Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Huntington Bancshares Incorporated — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while Huntington Bancshares Incorporated trades at $17.89 (market cap $36.22B). The key difference: Alnylam Pharmaceuticals, Inc. and Huntington Bancshares Incorporated are close in size by market cap, and Huntington Bancshares Incorporated pays a 3.47% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HBAN | |
|---|---|---|
Market Cap | $39.89B | $36.22B |
Sector | Health | Financials |
52-Week High | $491.22 | $19.27 |
52-Week Low | $278.09 | $15.02 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
HBAN trades at $17.87, up 0.62% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.25. Recent Q1 2026 earnings beat expectations with EPS of $0.26, and revenue for 2025 grew to $8.13B. The company maintains a solid net income margin of 25.13% and a P/E ratio of 13.75, indicating reasonable valuation. News highlights include expansion in Texas and a recent dividend payment, supporting positive sentiment.
The outlook for HBAN is positive, with growth driven by strategic acquisitions and organic loan expansion, though risks include integration challenges and competitive pressures in regional banking. Analysts are predominantly bullish, with 49% recommending buy, suggesting potential upside from current levels if earnings targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
